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A single dose polyanhydride-based vaccine platform promotes and
maintains anti-GnRH antibody titers
Abstract
Traditionally, vaccination strategies require an initial priming vaccination followed by an antigen boost to
generate adequate immunity. Here we describe vaccination against a self-peptide for reproductive sterilization
utilizing a three-stage vaccine platform consisting of gonadotropin releasing hormone multiple antigenic
peptide (GnRH-MAP) as a soluble injection coupled with subcutaneous administration of polyanhydride-
immobilized GnRH-MAP and a cyto-exclusive implant containing GnRH-MAP dendrimer-loaded
polyanhydride. This strategy generated and maintained cell-mediated and humoral immunity for up to 41
weeks after a single vaccination in mice with enhanced antibody avidity over time. All intact implants had a
grossly visible tissue interface with neovascularization and lymphocytic aggregates. Despite detectable
immunity, sterility was not achieved and the immune response did not lead to azoospermia in male mice nor
prevent estrus and ovulation in female mice. However, the vaccine delivery device is tunable and the
immunogen, adjuvants and release rates can all be modified to enhance immunity. This technology has broad
implications for the development of long-term vaccination schemes.
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Traditionally, vaccination strategies require an initial priming vaccination followed by an antigen boost to
generate adequate immunity. Here we describe vaccination against a self-peptide for reproductive ster-
ilization utilizing a three-stage vaccine platform consisting of gonadotropin releasing hormone multiple
antigenic peptide (GnRH-MAP) as a soluble injection coupled with subcutaneous administration of
polyanhydride-immobilized GnRH-MAP and a cyto-exclusive implant containing GnRH-MAP
dendrimer-loaded polyanhydride. This strategy generated and maintained cell-mediated and humoral
immunity for up to 41 weeks after a single vaccination in mice with enhanced antibody avidity over time.
All intact implants had a grossly visible tissue interface with neovascularization and lymphocytic aggre-
gates. Despite detectable immunity, sterility was not achieved and the immune response did not lead to
azoospermia in male mice nor prevent estrus and ovulation in female mice. However, the vaccine deliv-
ery device is tunable and the immunogen, adjuvants and release rates can all be modified to enhance
immunity. This technology has broad implications for the development of long-term vaccination
schemes.
 2018 Elsevier Ltd. All rights reserved.
1. Introduction
An optimal immune response to vaccination includes the gener-
ation and maintenance of protective levels of antibodies or cell-
mediated immunity. However, both of these responses rarely occur
after a single administration of a vaccine. The phenomenon of con-
comitant immunity wherein the host generates and maintains pro-
tective immunity after an infection illustrates that there are
mechanisms by which long-term immunity could be initiated
and maintained after a single vaccination [1]. For example,
resolved Leishmania major infection is a dynamic relationship
between surviving and dying parasites in the lesion and the result-
ing concomitant immunity is dependent upon short-lived non-
proliferating CD4+ T cells maintained by persistent antigen [2,3].
Development of a single-dose vaccine platform that mimics con-
comitant immunity, which could be adapted to different immuno-
gens and adjuvants, would be a significant advance towards
generating long-lasting protective vaccine responses.
An excellent model for such a platform are immunocastration
vaccines targeting gonadotropin releasing hormone (GnRH), a 10
amino acid peptide hormone conserved across many species that
is essential for sperm production in males and ovulation in females
[4]. Maintaining effective levels of anti-GnRH antibodies are criti-
cal for effective long-term immunocontraception [5]. Some impor-
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tant successes have been achieved with GnRH vaccines, such as
ImprovacTM for pigs, EquityTM for horses, BoprivaTM for cattle and
GonaconTM. All of these formulations use GnRH linked to various
carrier proteins with different adjuvants. GonaconTM is single
administration product registered for use in wildlife and feral
horses that has demonstrated durable long-term immunocastra-
tion. Notably, dogs and male cats respond suboptimally to Gona-
conTM and there remains a need to develop a multi-year single
administration vaccine for immunocastration that could be tuned
by adjusting the antigen, adjuvant and release rates to optimize
the immune response in multiple species [6–9].
Polyanhydrides have been studied extensively and are known
to be effective as a biocompatible micro- and nano-vaccine deliv-
ery platform that enhances immunity while protecting the
immunogen in a surface eroding hydrophobic solid monolith. The
rate of antigen release can be tuned by altering the degradation
characteristics of the PA chemistry and/or the surface area of the
PA exposed to hydrolysis [10–14]. The present study consisted of
polyanhydride copolymers with a molar composition of 20% 1,8-
bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) and 80% 1,6-bis
(p-carboxyphenoxy)hexane (CPH) (i.e., 20:80 CPTEG:CPH) due to
its ability to stabilize entrapped proteins and the slow surface ero-
sion characteristics of CPH-rich chemistries [10,15]. Additionally,
polymer chemistry can be used to modulate immune responses.
In the case of copolymers, this is typically achieved by varying
the copolymer composition. It has been shown that copolymer
composition can alter nanoparticle persistence and therefore the
bioavailability of antigen over time [16]. It has also been previously
demonstrated with polyanhydride-based nanovaccine formula-
tions that the chemistry of the carrier resulted in differential anti-
body titer, avidity, and IgG subclass switching in immunized
animals [17,18]. In another example, Haughney et al. reported that
varying copolymer chemistry altered the persistence of polyanhy-
dride nanoparticles as well as the kinetics and maturation of the B
cell response, including antibody titer, avidity, and specificity to
immunodominant linear epitopes of the target antigen [19].
In this study the vaccine platform has 3 stages, (1) an injection
of soluble GnRH-Multiple Antigenic Peptide (MAP) linked to Blue
Protein (BP) with alum to prime the immune system and initiate
antibody-mediated immunity, (2) a pressed solid rod of PA that
degrades at all surfaces over a timeframe compatible with a boost-
ing immunization that releases GnRH-MAP and MPLA adjuvant to
support a CD4+ T helper cell response [20], and (3) long-term vac-
cine release from a PVDF membrane-capped cytoexclusive implant
that encases a PA rod containing adjuvant free GnRH-MAP linked
by polyethylene glycol dendrimers. In the implant PA degradation
is limited to one surface and a diffusion barrier of collagen is placed
above the vaccine depot for theoretical passive immunoregulation
of antigen release by immune-complex deposition. We hypothe-
size that this design will promote extended immunity without
multiple injections [21–25]. The aim of the current study was to
assess gross and microscopic tissue changes associated with the
vaccine platform, determine if such a vaccine platform could gen-
erate and maintain immunity, as well as assess the histopathology
of reproductive tissue post-vaccination.
2. Materials and methods
2.1. Antigen Synthesis, formulation and adjuvants
GnRH was synthesized as an 8-subunit MAP (Pyr-
HWSYGLRPGQHWSYGLRPG) as described by Beekman et al. [26]
or as a GnRH-MAP linked to an 8 arm polyethelyne glycolated
40 K maleimide dendrimer (BioSynthesis, Lewisville, TX). Purity
was validated via HPLC by the manufacturer and greater than 50%.
For soluble vaccine formulations, Blue CarrierTM Protein (BP)
(Thermo Scientific) was coupled to GnRH-MAP via 1-Ethyl-3-(3-d
imethylaminopropyl)carbomide (EDC) crosslinking following man-
ufacturers recommendations [27]. GnRH-MAP-BP was washed
with sterile phosphate buffered saline (PBS) via centrifuge purifica-
tion with 20 kDa columns (Thermo Scientific). Successful crosslink-
ing was confirmed via western blot analysis.
2.2. Soluble antigen formulation
The soluble vaccine was comprised of either 300 lg GnRH-
MAP-BP (treatment) or sterile PBS (control) with 2 mg Alum
(Imject Alum, Thermo Scientific) in a volume of 100 lL.
2.3. Polyanhydride formulation
20:80 CPTEG:CPH copolymers were synthesized using melt
polycondensation as previously described [10]. The number-
average molecular weight and molar composition was quantified
using 1H NMR (DXR 500), specifically by end group analysis. The
20:80 CPTEG:CPH copolymers synthesized had a molecular weight
of 5800 Da with a polydispersity index (PDI) of 1.5 and 21,000 Da
with a PDI of 1.4, respectively.
2.4. Rod design
Polyanhydride rod design and synthesis is previously described
[25] using 208 mg PA, 100 lg of Monophosphoryl Lipid A (MPLA)
derived from Salmonella minnesota R595 (InvivoGen, San Diego,
CA) (treatment) with or without 300 lg of GnRH-MAP. The esti-
mated time for degradation from all surfaces is three months or
3.18 lg of GnRH-MAP released per day [28]. Dried mixtures of vac-
cine, PA, and MPLA were pressed in custom made mold under 2
metric tons pressure using a Carver press.
2.5. Implant design
The ultra high molecular weight polyethylene (UHMW-PE)
implant has been described previously [25]. The implant is 20
mm long with an internal diameter of 4 mm with a volume of
206 lL and capped with a 0.65 lm pore PVDF membrane (EMD
Millipore 3P DVPP00010 Durapor). To conserve GnRH-MAP den-
drimer antigen, 70 mg of PA containing 450 lg of dendrimer was
pressed as above and placed on top of pressed 70 mg of antigen-
free PA resulting in a 140 mg PA insert with the antigen containing
PA positioned towards the PVDF membrane. The estimated time to
degradation from a single exposed surface with a diameter of 0.4
cm and depth of 1 cm is ca. 38 months or 0.794 lg of vaccine
released per day [28]. For control group 7 (Fig. 1B) the implant con-
tained 140 mg of antigen-free polyanhydride. The PA was then lay-
ered with approximately 100 lL of 0.5% type 1 bovine collagen
(PureCol EZ Gel, Advanced BioMatrix, San Diego, CA) and cross-
linked as previously described [29]. The cap was then fixed with
n-butyl cyanoacrylate (VetbondTM, 3 M St. Paul, MN) and stored in
PBS at 4 C until use.
2.6. Animals
C3HeB/FeJ mice were purchased from Jackson Labs (Bar Harbor,
ME). All experiments with animals were in accordance with the
National Institutes of Health Guide for the Care and Use of Labora-
tory Animals and the Michelson Found Animals Foundation’s Pol-
icy for Animals Involved in Research, and were approved by Iowa
State University IACUC. All animals were at least eight weeks of
age. The number of animals per group was determined by a statis-
tical model based on prior studies with polyanhydride nanoparti-
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cles [30,31]. A 1 in. 27 gauge needle was used to inject the soluble
vaccine caudal to the rod and implant. For implantation all animals
weighed at least 20 g. Both the rod and implant were placed into
subcutaneous tissue along the right side of the dorsum under gen-
eral anesthesia with either an intraperitoneal injection of ketamine
(100 mg/kg) and xylazine (10 mg/kg) for experiment 1 and exper-
iment 2 males, or isofluorane inhalant anesthesia for experiment 2
females. The different experimental groups are outlined in Fig. 1B.
Some animals required topical medication and/or cage separation
to promote healing post-implantation. Animals were bled via the
saphenous vein using manual restraint in accordance with the
schedule shown in Fig. 1C.
2.7. Fluorescent GnRH ELISA
GnRH antibody determination was assayed via ELISA at 1:200
serum dilution in duplicate as described previously [32]. Briefly,
biotinylated-GnRH peptide (BioSynthesis) was added at 17.5 pmol
per well in PBS to NeutrAvidinTM-coated BSA-blocked Black Plates
(Thermo Scientific). Plates were incubated with polyclonal anti-
mouse IgG F(ab’)2-HRP (ThermoScientific),washed, developedwith
Amplex UltraRed Reagent, and stopped with Amplex Red Stop
Solution following manufacturer’s instructions (Thermo Scientific).
2.8. Avidity index
Antibody avidity was assayed via as previously described [33].
Briefly, plates were coated with 5 lg/mL purified GnRH-MAP, incu-
bated at 1:200 serum dilution, samples were treated with a serial
dilution of 6.0 M sodium thiocyanate (Sigma Aldrich) in duplicate
and developed with anti-mouse-HRP (Thermo Scientific) and
Ultra-TMB (Thermo Scientific) substrate as directed by the
manufacturer.
2.9. Cytokine assay
For in vitro antigen-recall cytokine responses, single cell sus-
pensions of splenocytes were cultured in duplicate and super-
natants were harvested 5 days post-stimulation as previously
described [34]. IFN-c, IL-5, and IL-10 levels were measured using
a multiplexed magnetic bead assay (Luminex, Austin, TX) using a
standard curve created with commercial cytokines per manufac-
turer’s instruction.
2.10. Tissue collection and histology
At the time of euthanasia, testicles were excised and measured
with calipers for length and width to estimate testicular volume
and then placed in Davidson’s fixative. Skin at the implantation
site, ovaries and uterine tissue were harvested and placed into
10% neutral buffered formalin. Tissues were embedded in paraffin
and processed into 10 lm tissue sections and stained with hema-
toxylin/eosin as previously described [35]. A board certified veteri-
nary pathologist (Hostetter) was blinded to the experimental
groups and assessed all sections of implant sites and/or rods for
inflammation, macrophages, lymphocytes and plasma cells as well
Fig. 1. Experimental design. (A) Schematic of the 3 stage platform. (B) Experimental groups 1–6 for experiment 1 and groups 1–8 for experiment 2. (C) Bleeding schedule for
experiment 1 (top) and experiment 2 (bottom).
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as uterine histology. Uterine tissue was determined as diestruswith
low cuboidal epithelium, few mitosis in epithelium, condensed
stroma, no dilation, or proestrus with dilation of the uterine lumen,
moderate mitoses and neutrophils, or estrus with tall cuboidal
epithelium, numerous mitosis and low neutrophils, or metestrus
with epithelial degeneration and low mitosis [36]. Testes and epi-
didymis were assessed for mature sperm. Ovaries were scored for
number of corpus luteum (CL)’s, degenerating CL’s, and primary,
secondary or tertiary follicles and cysts per tissue section.
2.11. Statistics
Standard ANOVA approaches with the Tukey or Bonferroni cor-
rection were used as indicated. Analysis of covariance was
employed for the avidity index assay [37]. Log ratios = log(Y/X)
where Y is antibody fluorescence at the experimental endpoint
and X is antibody fluorescence at week 0. If Y/X = 1 then log(Y/
X) = 0. A non-zero log ratio indicates detectable antibodies [38].
3. Results
3.1. Vaccine device
A 12 week dose response study (Supplementary Fig. 1) and a
study with Alum and MPLA adjuvants (Supplementary Fig. 2) indi-
cated that high doses of between 100 lg and 500 lg of GnRH-MAP
linked toBP inAlumgenerated thehighest antibody levels andMPLA
as an adjuvant with 300 lg GnRH-MAP alone enhanced cell-
mediated immunity and further reduced testicular size and altered
expression of luteinizing hormone receptor (LHR) protein and
insulin-like factor 3 (Insl3) mRNA, two molecules regulated by
testosterone [39–41]. Although sterility was not achieved in male
or femalemice in this short time frame (data not shown) the studies
defined the antigens and adjuvants for the vaccine platform design.
The vaccine platform consisted of three independent parts; a
soluble injection of 300 lg GnRH-MAP-BP with alum (Sol); a
20:80 CPTEG:CPH PA-rod containing 300 lg GnRH-MAP and MPLA
with all surfaces exposed to tissue (Rod); a cytoexclusive diffusion
barrier implant containing 450 lg GnRH-MAP linked to a 8 arm
PEG dendrimer in a 20:80 PA-rod limiting degradation to 1 surface
(Implant, Fig. 1A). In experiment 1 there were six experimental
groups (groups 1–6) with 4 male and 4 female mice per group
(Fig. 1B). In the first experiment the implant was well-tolerated
although five male mice lost their implants (out of 16 implants)
randomly over the course of seven months (Table 1). These animals
would present with the PVDF membrane end of the device exposed
through the skin surface, or the device removed from the animal.
Only one animal was terminated because of exposure of a polyan-
hydride rod, which became exposed within two weeks. All group 2
males lost their implants by seven months (30 weeks) prompting
termination of the experiment. Female mice tolerated the implants
extremely well for 10 months (38 weeks) when four animals from
three different groups lost their implant. This experiment was ter-
minated at 41 weeks.
We repeated these experiments adding two control groups
(Fig. 1B, groups 1–8). Female mice tolerated the implants for two
months when 40% of the implants (8 out of 20) were lost through
weeks 8–10. All of the female mice, whether in the first or second
experiment, lost their implants over the same four-week period.
Males lost four implants of which only two were lost during the
same weeks. This second experiment was terminated at 14 weeks,
in part due to the loss of implants.
Gross examination of the implant sites showed that all PA-rods
and implants were imbedded in subcutaneous fat with vessels vis-
ibly infiltrating the area around the PA-rod and implant cap. All
implants had an intact PVDF membrane and the cap had a visible
tissue interface that varied in color from red to white (Figs. 2A–
C; Supplementary Fig. 3). The persistence of the collagen diffusion
barrier within the implant varied, with experiment 1 males having
the lowest success rate (estimated to be <30% with collagen pre-
sent) and the females having the highest success rate (75% with
collagen present). In the second experiment collagen was present
in 50% of the implants of females and 40% of males. If no collagen
was visible the barrier space was full of cell free straw colored clear
fluid. One male from experiment 2 group 7 had thick white puru-
lent material at the implant site.
3.2. Histology
Sections of haired skin, panniculus, and skeletal muscle from
the PA-rod and/or implant site from both experiments were fixed
for examination. In multiple sections PA-rods were present in the
panniculus accompanied by mild to marked inflammatory cell
infiltrates. The PA-rod was acellular amphophilic to eosinophilic
fibrillary material that was often fragmented (Fig. 2E). The PA-
rods were typically bordered by moderate to large numbers of
macrophages enmeshed in immature fibrous connective tissue.
There were occasional small to medium lymphoid aggregates that
bordered the PA-rod or that were in the adipose tissue adjacent to
the PA-rod (Fig. 2D, E). Low numbers of plasma cells and low to
moderate numbers of neutrophils were occasionally seen in the
subcutis around the PA-rod. In some sections there were well-
delineated round to oval foci of fibrous tissue and macrophage
aggregates that were often associated with a distinct clear space
(presumed implant space). In these foci there was moderate fibro-
sis immediately around the clear space that was bordered by mod-
erate to large numbers of macrophages with foamy, amphophilic to
basophilic granular cytoplasm. There were multiple foci of neovas-
cularization with thin wall endothelial lined capillaries or lym-
phatics within and adjacent to foci of fibrosis (Fig. 2F, G).
There were no differences in testicular size between any groups
in either experiment 1 or 2 (data not shown) and mature sperm
was found in the epididymis from all male mice (data not shown).
All treatment groups had some ovulating female mice with no sig-
nificant differences in ovarian structures such as CL’s, degenerating
CL’s, and follicles (data not shown). Histological sections of the
uteri of female mice in experiment 1 showed that animals were
cycling with only group 2 having all animals in either diestrus or
proestrus (Table 2, Fig. 3). The uterus was distended with fluid in
14 out of 24 animals in experiment 1 with groups 2, 4, and 6 most
severely affected and group 3 having two animals with a purulent
endometritis (Table 2). Female mice in experiment 2 were not
scored for uterine changes.
3.3. Antibody levels and recall responses
ELISA results show anti-GnRH antibody levels at 1:200 serum
dilution for experiment 1 females (Fig. 4A) and males (Fig. 4B)
for all experimental groups over time. Using the log ratio of the
wavelength at the last week versus the prebleed timepoint shows
that all females with an implant, excluding the implant alone, had
antibodies at 10 months post-vaccination (groups 1, 2, and 4).
Group 1 was significantly higher than all other groups at week
41 (one-way ANOVA with Bonferroni correction). All males had
detectable anti-GnRH antibodies with group 1 having highest
levels at week 30 (one-way ANOVA with Bonferroni correction).
The dynamic-predicted log ratio plots over time for each group
are shown in Supplementary Fig. 4. Avidity index curves for anti-
bodies from group 1 females and males show significantly
enhanced antibody avidity at 41 and 30 weeks, respectively (p <
.001, analysis of covariance) (Fig. 4C). Spleen cells isolated at the
R.G. Schaut et al. / Vaccine 36 (2018) 1016–1023 1019
termination of the experiments and restimulated with GnRH-MAP
showed significant increases in IFN-c (p = .0056) and IL-5 (p =
.0158) for females with no group being significantly different.
Males had a significant increase only in IFN-c (p = .0056). There
were no significant increases in IL-10 for either males or females
(Fig. 4D, E). For experiment 2, antibody levels were measured by
ELISA at the termination of the experiment at 14 weeks post-
vaccination. There were no significant differences between groups
for females (one-way ANOVA with Tukey correction) whereas in
males both groups 1 and 3 were significantly different than group
7 (p = .0028 one-way ANOVA with Tukey correction) (Supplemen-
tary Fig. 4).
4. Discussion
We sought to develop a vaccine device designed to mimic the
principles of concomitant immunity in which infection by a patho-
gen maintains protective immunity within the host via dynamic
antigen persistence [3,42,43]. In pursuit of this goal we developed
a three-stage vaccine platform designed to prime, boost and main-
tain immunity to GnRH-MAP after a single vaccination.
Several promising aspects of the three-stage vaccine platform
were discovered. The rods were well-tolerated in both experiments
with only one animal out of 72 animals losing the rod. Detectable
antibodies in 14 out of 16 animals in group 6 (rod only) from both
Table 1
Implants lost.
Experiment 1 Experiment 2
Group Sex Time post vaccine (weeks) Group Sex Time post vaccine (weeks)
2 Male 16 1 Male 10
2 Male 23 2 Male 3
2 Male Unknown 2 Male 8
2 Male 30 4 Male 1
3 Male 1.5 1 Female 8
4 Male 10 1 Female 9
1 Female 38 1 Female 11
2 Female 38 4 Female 8
4 Female 38 4 Female 9
4 Female 38 4 Female 11
5 Female Unknown
7 Female 9
7 Female 1
Exp. 1 termination 41 week; Exp. 2 termination week 14, Italics/bold = animal euthanized.
Fig. 2. Representative images of the implant and rod at 10 months post-vaccination in female mice. (A) Implant (red arrow), rod (black arrow) are visible in subcutaneous
tissue. (B) The PVDF end of the implant. (C) Closer image of rod. (D-G) Representative histology of the site of implant and/or rod with lymphocytic aggregates (black arrows),
PA (arrow heads) and blood vessels (red arrows). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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experiments indicates that (1) GnRH-MAP maintains immuno-
genicity after being formulated with PA and (2) sufficient immuno-
gen is released from the rod with MPLA adjuvant to elicit an
immune response in a majority of animals. Although at the termi-
nation of the experiments all PA-rods were grossly similar to their
original size and shape (Fig. 2) degradation could be extensive with
the overall shape of the PA-rod remaining unchanged [44–46],
although future studies are needed. Overall the implants were tol-
erated moderately well except for a four-week period in which
female mice in both experiments 1 and 2 lost 25% and 40% of the
implants, respectively, whereas male mice lost 20–30% of their
implants randomly over the course of the experiments (Table 1).
It is reasonable to expect larger animals will have a significantly
higher implant success rate. All implants assessed at the end-
point of experiment 1 or 2 had a grossly visible tissue interface
formed on the PVDF membrane with macrophages, lymphocytic
aggregates and neovascularization (Fig. 2). Although the fluid
dynamics at the interface of the PVDF membrane is unknown,
the space above the PA-rod was always fluid-filled or remained
filled with collagen. Published studies of glucose transport in
immune-isolation chambers indicate a dynamic relationship
between fluids within implants and plasma for pore sizes as small
as 10 nm [47]. In experiment 1, when the dynamics of the antibody
response over the entire timecourse is compared between groups
based on their predicted log ratios, group 2 (priming dose and
implant) is different than group 3 (priming dose and rod) indicat-
ing that the implant design has a significant effect on the immune
response that is different then that of the rod (Supplemental Fig. 5).
Overall the components of the vaccine platform promoted effective
priming, boosting and long-term maintenance of cell-mediated
and antibody responses to an immunogen for up to 41 weeks with
significant affinity maturation. Future studies are required to
determine if antibody affinity is enhanced through any immune
feedback mechanism [48,49].
The antibody levels in experiment 2 at the 14 week termination
timepoint were inconsistent both within and between treatment
groups. This could be a result of unknown inconsistencies gener-
ated during either the synthesis of the vaccine platform itself or
its administration. Clearly the antibodies generated were not suffi-
cient to promote sterility in mice in either experiment. This result
suggests that higher antibody levels are warranted which could be
addressed with different immunogen constructs or adjuvants.
However, higher IL-10 levels in GnRH-MAP-BP vaccinated animals
compared to BP only vaccinated animals (Supplemental Fig. 1) sug-
gest that immunoregulatory mechanisms may limit the immune
response to GnRH self-peptide and highlight another possible bar-
rier in generating consistent long-term immunocastration using
GnRH-based vaccines [50].
To generate and maintain immunity to a vaccine immunogen
we designed a vaccine platform that would prime, boost and then
maintain immunity with different antigen release mechanisms. To
avoid tolerance and promote active immunity an immune feed-
back mechanism is proposed in which antibody levels could theo-
retically influence immunogen release by the formation of
immune-complexes within a diffusion barrier between the vaccine
depot and the implant opening. The vaccine platform is capable of
maintaining both antigen-specific B cell and T cell responses for at
least 10 months with a single dose. The sustained immunity gener-
ated with the vaccine platform supports further experiments to
optimize antibody levels and/or determine the effectiveness of
the current platform in other species, as well as determine if the
vaccine platform is effective with a pathogen-specific vaccine.
The vaccine platform is amenable to alternative designs and the
immune response in different species could be targeted by adjust-
ing the immunogen, dose, adjuvant, and release rates.
Table 2
Reproductive status of females.
Group # Status Lumen fluid
1 1 D 0
2 E 1
3 E 0
4 E 3
2 1 P 0
2 D 3
3 D 3
4 D 3
3 1 D 0
2 P 2
3 a
4 a
4 1 D 0
2 P 2
3 E 3
4 M 3
5 1 D 0
2 M 0
3 D 0
4 D 2
6 1 D 3
2 M 2
3 E 2
4 P 3
D = diestrus, E = estrus, P = proestrus, M = metestrus. Reproductive status scoring
rubric in materials and methods. 0 = no fluid, 1 = slight dilation, 2 = low # distended
segments (<3/uterus), 3 = diffuse distension,
a =Purulent endometritis.
Fig. 3. Uterine histology with grade 3 distension (A) and estrus (B). A representative tissue section from a group 1 mouse at 10 months post-implantation. Scoring is described
in materials and methods and Table 2.
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Fig. 4. Vaccine platform maintains antibody levels, recall responses and promotes enhanced avidity over time for animals in experiment 1. Anti-GnRH levels of (A) female
mice and (B) males at time points indicated at serum dilution of 1:200. Mean ±SD. (C) Avidity index for antibodies from group 1 female (left) and male (right) mice at the
indicated weeks post-vaccination. Each circle represents mean of 4 animals. (D and E) Cytokine levels, as indicated, from recall responses of spleen cells stimulated with
GnRH-MAP for females (D) and males (E). Bars are mean of stimulated group ±std. dev. Each closed circle represents an individual animal. Open symbols are unstimulated
levels.
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